What is Nouscom?
Nouscom is a specialized biotechnology enterprise headquartered in Basel, Switzerland, with additional operations in Rome, Italy. The company focuses on the intersection of oncology and immunology, leveraging engineered viral vectored vaccines and oncolytic viruses to stimulate a potent immune response against tumors. By utilizing proprietary platforms that encode multiple tumor neoantigens, Nouscom addresses the critical need for both off-the-shelf and personalized therapeutic solutions. Their market position is defined by a commitment to rigorous scientific validation and the development of safe, effective immunotherapies designed to improve patient outcomes in diverse cancer indications.
How much funding has Nouscom raised?
Nouscom has raised a total of $142.2M across 3 funding rounds:
Series A
$13.6M
Series B
$46.6M
Series C
$82M
Series A (2016): $13.6M with participation from LSP Ventures and Versant Ventures
Series B (2017): $46.6M led by Versant Ventures, 5AM Ventures, Life Sciences Partners, and Abingworth
Series C (2024): $82M supported by Angelini Ventures, Andera Partners, Revelation Partners, X-Gen Ventures, and Bpifrance
Key Investors in Nouscom
Versant Ventures
A premier venture capital firm that partners with exceptional entrepreneurs to build and fund innovative biotechnology companies globally, leveraging extensive pharmaceutical and scientific expertise.
5AM Ventures
A life science-focused venture capital firm that backs early-stage biotech and healthcare innovators, partnering closely with founders to shape companies and fund rigorous scientific research.
Andera Partners
A major European private equity player with a dedicated life sciences team that has invested in over 75 biotech and medtech companies since its inception.
What's next for Nouscom?
With the recent infusion of capital, Nouscom is poised to scale its clinical operations and further validate its immunotherapy platforms. The strategic focus will likely center on advancing its lead candidates through critical trial milestones, potentially expanding its footprint in the global oncology market. As the company matures, the emphasis will shift toward optimizing manufacturing processes and exploring potential partnerships to enhance the commercial viability of its pipeline. The continued backing from high-profile life sciences investors provides the necessary runway to navigate the complexities of late-stage drug development and regulatory approval, ensuring that Nouscom remains at the forefront of the next wave of cancer treatment innovation.
See full Nouscom company page
